Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Recall of Two Lots of Cytomel 25 mcg (Liothyronine) Tablets
King Pharmaceuticals, Inc has voluntarily recalled two lot numbers of Cytomel 25 mcg (Liothyronine Sodium) Tablets with product code number NDC 60793-116-0. Lot numbers 52215 (exp 09/2009) and 52216 (exp 09/2009) are being recalled because the tablets of these lot numbers were sub-potent (contained less than the labeled strength) 12 months after manufacturing. This recall notice only applies to these two lot numbers. Cytomel is the brand name for liothyronine and is used primarily to treat hypothyroidism. No other Cytomel or liothyronine lot numbers were involved in this recall. For more information, please visit: http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm181251.htm
Learn More

Recall of a Single Lot of Actavis / Catalent Bupropion Extended-Release Tablets 150 mg
Actavis South Atlantic LLC and Catalent Pharma Solutions have recalled a single lot number of Twice a Day Bupropion Hydrochloride Extended-Release Tablets, 150 mg, labeled with product code NDC 67767-133-60. The lot number 0805699A is being recalled because the tablets in this lot failed impurity tests and contain additional inactive ingredients. Bupropion is used in the treatment of depression and is also used to help people stop smoking. Bupropion is sold under many different brand names (including Aplenzin, Wellbutrin and Zyban) and is available in different strengths. No other brands or strengths of bupropion are involved in this recall. For more information, please visit: http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm181251.htm
Learn More

Date Published Title Drug Source
2009-10-23 Recall of Two Lots of Cytomel 25 mcg (Liothyronine) Tablets Liothyronine FDA
2009-10-25 Recall of a Single Lot of Actavis / Catalent Bupropion Extended-Release Tablets 150 mg Bupropion FDA
2009-10-25 Recall of Several Lots of Teva / Ivax Atenolol 25 mg and 50 mg Tablets Atenolol FDA
2009-10-26 Update on Risk of Progressive Multifocal Leukoencephalopathy (PML) with Use of Rituxan Rituximab FDA
2009-10-28 Recall of All Accusure Insulin Syringes Insulin Manufacturer
2009-10-28 Recall of All Accusure Insulin Syringes Insulin Aspart FDA
2009-10-28 Recall of All Accusure Insulin Syringes Insulin Lispro FDA
2009-10-28 Recall of All Accusure Insulin Syringes Insulin Glargine FDA
2009-10-28 Newer Antipsychotics Associated with Significant Weight Gain With Short-Term Use in Children and Adolescents Aripiprazole MediGuard CRT
2009-10-28 Newer Antipsychotics Associated with Significant Weight Gain With Short-Term Use in Children and Adolescents Olanzapine MediGuard CRT
2009-10-29 Newer Antipsychotics Associated with Significant Weight Gain With Short-Term Use in Children and Adolescents Quetiapine MediGuard CRT
2009-10-29 Newer Antipsychotics Associated with Significant Weight Gain With Short-Term Use in Children and Adolescents Risperidone MediGuard CRT
2009-11-03 Reports of Altered Kidney Function in Patients Using Byetta Exenatide FDA
2009-11-04 FDA Answers Common Questions about Tamiflu Oseltamivir FDA
2009-11-04 FDA Answers Common Questions About Relenza Zanamivir FDA
2009-11-12 Recall on Several Lots of Teva / Novopharm Clonazepam 0.5 mg and 1 mg Tablets Clonazepam FDA
2009-11-12 Recall on a Single Lot of Temodar Capsules 5 mg Temozolomide FDA
2009-11-12 Recall on a Single Lot of Invega Extended Release 6 mg Tablets Paliperidone FDA
2009-11-14 Possible Contamination of Cerezyme Imiglucerase FDA
2009-11-14 Possible Contamination of Fabrazyme Agalsidase Beta FDA